FDA approves skin cancer vaccine by...? — June 30, 2027

    13% chance

    Yes13%Polymarket (global): price for reference, not tradable in the USYes14¢14¢ after fees
    No87%Polymarket (global): price for reference, not tradable in the USNo88¢88¢ after fees
    Resolves
    Jun 30, 2027
    Volume
    $75.6K
    24h
    $15.0K
    Liquidity
    $8.5K
    Polymarket (global): price for reference, not tradable in the USListed on 1 venue

    Chance over time

    Polymarket USPolymarket USCFTC-regulated

    Deposit $10, get $25

    Trading bonus for new sign-ups.

    Sponsored · We may earn a commission · 18+ · Trade responsibly · 1-800-GAMBLER

    Signals

    Quiet market: no big moves or venue gaps in the last 24 hours.

    Every venue’s price

    1 venue
    ChanceBest
    Yes13%—Polymarket (global): price for reference, not tradable in the US14¢14¢ after fees
    No87%—Polymarket (global): price for reference, not tradable in the US88¢88¢ after fees

    Each share pays $1 if it’s right. Green marks the cheapest venue after fees; every price opens that venue’s market.

    Before you trade

    Fee Impact at These Prices

    Polymarket (global): price for reference, not tradable in the USPolymarketat 14¢: exit costs ~0.48¢/contract
    Full calculator

    How each venue settles it

    Polymarket (global): price for reference, not tradable in the USPolymarket (global)

    This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, togethe…

    Full rules on Polymarket (global) ↗

    About this market

    Category
    Culture
    Resolves
    Wed, June 30, 2027
    Polymarket (global): price for reference, not tradable in the USCompared across 1 venue

    In the news

    Discussion

    Sign in to join the discussion

    Sign In

    More in Culture

    All Culture